Suzhou Industrial Park Heshun Electric
300141
Guangdong Xiongsu Technology Group
300599
Sichuan Chuanhuan Technology
300547
Shanghai Wisdom Information Technology
301315
KANGNONG SEED
837403
CN Stock MarketDetailed Quotes
002734 Limin Group
- 8.18
- +0.20+2.51%
Market Closed Dec 27 15:00 CST
3.00BMarket Cap32.85P/E (TTM)
8.24High7.95Low66.93KlotVolume7.98Open7.98Pre Close54.37MTurnover2.06%Turnover Ratio48.40P/E (Static)366.86MShares9.9052wk High1.23P/B2.66BFloat Cap4.7052wk Low8.78Limit Up324.82MShs Float20.95Historical High7.18Limit Down3.63%Amplitude2.21Historical Low0.35Dividend TTM8.12Avg Price33.92KlotAsk4.28%Div YieldTTM100Lot Size31.96KlotBid
Limin Group News
Limin Group (002734.SZ): Signed a global strategy cooperation agreement with The Cigna Group.
On December 20th, Gelonghui reported that Limin Group (002734.SZ) announced that on December 19, 2024, the company signed a "Global Strategy Cooperation Agreement" with Chengdu Green Cigna Biotechnology Co., Ltd. (hereinafter referred to as "Green Cigna Biotechnology"). Both parties will focus on new biopesticides based on underlying technologies such as small peptide extraction, molecular modification, and synthetic biology, jointly creating, researching, and promoting new agricultural small peptide biological products.
Limin Group (002734.SZ): Limin Chemical has been recognized as a high-tech enterprise.
Liming Group (002734.SZ) announced recently that the national "High-tech Enterprise Recognition Management Work Website" published...
Limin Group (002734.SZ): has a production capacity of 6000 tons of glufosinate-ammonium and 2000 tons of bio-based refined glufosinate-ammonium.
On December 4, Gelonghui reported that Limin Group (002734.SZ) stated in a recent investor relations activity that the company's layout in herbicides is relatively small, with a glyphosate production capacity of 6,000 tons, a bio-based refined glyphosate capacity of 2,000 tons, a nitrosulfonylacetic acid capacity of 1,000 tons, and a cyclic sulfonamide capacity of 500 tons. Currently, herbicide products are at historically low prices, and product prices and gross margins will face certain pressure for a period of time. Limin Group continues to increase investment in technology research and development, continuously improving existing products through technological transformation, cost reduction, and efficiency enhancement to strengthen product competitiveness. The company remains bullish on glyphosate.
Limin Group (002734.SZ): Core products include Daisen manganese zinc, Baijuns clear, performing well in the market.
Gelonghui December 4th | limin group (002734.SZ) stated in recent investor relations activities that the company's core products include Daisen manganese zinc, Baijunclear, etc., with good market performance. After acquiring Weiyuan Biochemistry, the company strengthened its insecticide business, owning the third-ranked domestic production capacity of avermectin and 800 tons of methomyl salt. The market fill price of avermectin rose from 0.35-0.36 million yuan at the end of last year to 0.46 million yuan, an increase of nearly 30%. The price of methomyl salt rose from 0.46 million yuan to 0.65-0.66 million yuan, with the price of 95% concentration products performing better.
Can Limin Group Co.,Ltd.'s (SZSE:002734) Weak Financials Pull The Plug On The Stock's Current Momentum On Its Share Price?
Limin Group (002734.SZ): During the current period, the market for the raw material of Bacillus thuringiensis is in short supply.
Gelonghui reported on November 26 that limin group (002734.SZ) stated on the investor interaction platform that the market for the original drug Baijunqing is in short supply, leading to price increases, while the prices of major raw materials remain stable. The company's subsidiary, Xinhahe, has a production capacity of 0.03 million tons per year, accounting for about 47% of the global capacity. Currently, the company's products are in a scheduled delivery status, and market demand and price expectations are optimistic.
limin group (002734.SZ) has repurchased 3.83% of its shares, spending approximately 0.1 billion yuan.
Limin Group (002734.SZ) announced that, as of October 31, 2024, the company has completed the repurchase program...
Limin Group (002734.SZ): The synthetic biology laboratory has been completely renovated and the new additional experimental equipment has arrived.
On November 5th, Limin Group (002734.SZ) stated on the investor interaction platform that the newly planned synthetic biology laboratory of the company has been renovated. The newly added experimental equipment has arrived and is currently being debugged and accepted. At the same time, the company has expanded cooperation with universities and research institutions, and some new projects have started pre-research and project evaluation. In the third quarter, the company obtained 7 new invention patents and 4 new utility model patents; as of September 30, 2024, a total of 138 invention patents, 134 utility model patents, and 15 design patents have been obtained.
Limin Group (002734.SZ) signed a strategic cooperation agreement with Changke Biology.
Gelonghui October 28th | Limin Group (002734.SZ) announced that on October 21, 2024, the company signed a "Strategic Cooperation Agreement" with Xiamen Changke Biological Engineering Co., Ltd. (referred to as "Changke Biology"), the two parties will jointly work on developing bacteriophage bio-pesticides based on synthetic biology technology and phage technology as underlying technologies, creating and developing novel agricultural phage bio-products for promotion and application. According to the agreement, the two parties will jointly create and develop new bacteriophage-based bio-pesticides; apply for registration certificates for bacteriophage bio-pesticides; collaborate on sales of bacteriophage products.
Limin shares: report for the third quarter of 2024
Limin Group (002734.SZ): The net income for the first three quarters was 51.1995 million yuan, a year-on-year increase of 132.76%.
Gelonghui October 27th｜Limin Group (002734.SZ) announced that in the first three quarters of 2024, revenue was 3.344 billion yuan, a decrease of 1.58% year-on-year; net income attributable to shareholders of the listed company was 51.1995 million yuan, a year-on-year increase of 132.76%, with basic earnings per share of 0.14 yuan.
limin group (002734.SZ) distributed 1.5 yuan per 10 shares for the semi-annual period, with a record date of October 17th.
limin group (002734.SZ) announced that the company will implement the interim equity distribution for the first half of 2024, with a distribution of 10...
limin group (002734.SZ): The products exported to Southeast Asia are mainly self-exported, and some are sold through foreign trade companies.
Gelonghui October 11th | limin group (002734.SZ) stated on the investor interactive platform that the company's products exported to Southeast Asia are primarily self-exported, some are sold through foreign trade companies. The company's products such as dendrobium manganese zinc, benzoic acid etherazole, and pyraclostrobin are used as mainstream fungicides in the Southeast Asian market, with relevant certificates for local independent registration and authorized registration. The Southeast Asian market has a high acceptance of patented new agricultural pesticide products, and the registration policies are similar to those in China, making it an important overseas target market for the company's future layout.
Limin Group Expects Up to 141% Profit Jump in January-September Period
Limin Co., Ltd.: The company\'s performance forecast for the first three quarters of 2024
Limin Group (002734.SZ) announced a forecasted increase, with an expected net income of 49 million yuan to 53 million yuan for the first three quarters, an increase of 122.76% to 140.95%.
Limin Group (002734.SZ) released a performance forecast for the first three quarters of 2024, expecting the attributable profits to the listed...
Limin Group (002734.SZ): signed a strategic cooperation agreement with Zhi Sheng You Gu.
Limin Group (002734.SZ) announced on September 25th, 2024, Limin Holding Group Co., Ltd. and Shanghai Zhisheng Yougu Biotechnology Co., Ltd. (hereinafter referred to as "Zhisheng Yougu") signed a "Global Strategy Cooperation Agreement" based on their respective global strategy layouts and business advantages, jointly dedicated to synthetic biotechnology, jointly creating and developing, and promoting the application of new RNA biological pesticides. Further enhance the company's core competitiveness and sustainable development capabilities, and contribute to the safe, green, and healthy development of agriculture. Both parties jointly create and develop targeted and environmentally friendly products.
Limin's Unit Gets Nod to Set Up Multifunctional Plant in China's Xuzhou City
Limin Group (002734.SZ): Subsidiary obtains investment project filing certificate
On September 18th, Gelonghui announced that Limin Group (002734.SZ) recently announced that its wholly-owned subsidiary, Limin Chemical Co., Ltd. (hereinafter referred to as Limin Chemical), has obtained the "Jiangsu Province Investment Project Filing Certificate" issued by the Xuzhou Industrial and Information Bureau [Filing Certificate No.: Xuzhou Industrial and Information Backup (2024) No. 3], The specific details are as follows: 1. Project name: Annual production of 100 tons of new efficient multifunctional pesticide raw material technology improvement project. 2. Filing approval institution: Xuzhou Industrial and Information Bureau. 3. Project overview: In order to further enhance the company's core competitiveness, it plans to invest in the construction of this project. The project plans to invest 50 million.
limin group (002734.SZ): Currently, the company's API production capacity is 0.1027 million tons, and the formulation production capacity is 0.1144 million tons.
Limin Group (002734.SZ) stated on the investor interaction platform on September 11 that the company has the advantage of a complete industry chain in the field of biologically fermentation, semi-synthetic biology, and formulation processing. It has advanced biologically fermentation technology, chemical synthesis technology, and formulation compatibility technology, which gives it advantages in terms of product cost, quality, and supply. Currently, the company's capacity for raw materials is 0.1027 million tons, and the capacity for formulation is 0.1144 million tons. The capacity utilization rate in 2023 is 68.35% for raw materials and 85.28% for formulations. In the first half of this year, the production of raw materials increased by 16.59% year-on-year, and the production of formulations increased by 19%.
